Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 0.65 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 12/20 | 0.64 |
| ▸ | NPC1 | O15118 | 11/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719539 | 0.81 | MAPT (0.69) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL16408442 | 0.81 | MAPT (0.69) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL19926278 | 0.81 | MAPT (0.68) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL20320421 | 0.80 | MAPT (0.67) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL10927961 | 0.79 | MAPT (0.66) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL11577752 | 0.78 | SMN1; SMN2 (1.00) | MAPTRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL23401154 | 0.77 | MAPT (0.62) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL26836390 | 0.77 | MAPT (0.62) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL27217187 | 0.77 | MAPT (0.62) | MAPTCDK8ACVR1RAB9ANPC1 | |
| SCHEMBL13974933 | 0.77 | MAPT (0.62) | MAPTCDK8ACVR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590340-B1 | INTERMEDIATES FOR THE SYNTHESIS OF FUNGICIDAL PYRAZOLES | FMC CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-115074760-B | Electrochemical synthesis method of 5-aminopyrazole-4-thiocyanate compound | 阜阳师范大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115074760-A | Electrochemical synthesis method of 5-aminopyrazole-4-thiocyanic acid ester compound | 阜阳师范大学 | 2022-09-20 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9969694-B2 | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | Array BioPharama Inc. (US) | 2015-06-18 | — | — | US | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078322-A1 | THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078328-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078408-A1 | BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20090221838-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLES | LONZA AG (CH) | 2009-09-03 | — | — | US | disclosed |
| EP-1919876-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES | LONZA AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020098-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES | LONZA AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221838-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLES | CYP3A5, CBR3, CYP3A4 | MAPT 2778/4885CDK8 1190/4885ACVR1 2081/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | MAPT 464/4885CDK8 185/4885ACVR1 1303/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | MAPT 118/4885CDK8 227/4885ACVR1 2392/4885 |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | MAPT 118/4885CDK8 227/4885ACVR1 2392/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885CDK8 185/4885ACVR1 1303/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885CDK8 185/4885ACVR1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.